Nitnib 12.5mg is a prescription medication used to treat certain types of cancer, including:
- Gastrointestinal stromal tumors (GIST)
- Pancreatic neuroendocrine tumors (pNET)
- Advanced renal cell carcinoma (RCC)
It is a tyrosine kinase inhibitor that works by blocking the action of specific enzymes that are involved in the growth and proliferation of cancer cells.
Composition:
Each tablet of Nitnib 12.5mg contains 12.5mg of sunitinib.
Mechanism of Action:
Sunitinib works by:
- Blocking the action of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), which are involved in the growth and proliferation of cancer cells
- Inhibiting the formation of new blood vessels that feed the tumor
- Reducing the growth and proliferation of cancer cells
Uses:
Nitnib 12.5mg is used to treat certain types of cancer, including:
- Gastrointestinal stromal tumors (GIST)
- Pancreatic neuroendocrine tumors (pNET)
- Advanced renal cell carcinoma (RCC)
Dosage:
The recommended dosage of Nitnib 12.5mg is:
- 12.5mg taken orally once daily, with or without food
Side Effects:
Common side effects of Nitnib 12.5mg include:
- Diarrhea
- Fatigue
- Nausea and vomiting
- Abdominal pain
- Rash
- Constipation
- Decreased appetite
Recommendation:
Nitnib 12.5mg is recommended for patients who have not responded to previous therapy for their specific type of cancer. Patients should also be advised to monitor their liver function and thyroid function regularly during treatment.
Important Note:
Patients should not take Nitnib 12.5mg if they have a history of severe allergic reactions, bleeding disorders, or kidney problems. Patients should also inform their healthcare provider if they have any underlying medical conditions, such as liver or kidney problems, before taking Nitnib 12.5mg.
Some common brands of sunitinib include:
- Sutent (Pfizer)
- Sunitinib (Pfizer)
Please note that Nitnib 12.5mg is not available in all markets and may be approved for different indications and dosages in different regions.
Reviews
There are no reviews yet.